The antiserum was produced against a chemically synthesized phosphopeptide derived from the region of human 4E-BP1 that contains threonine 46. The sequence is conserved in human, mouse and rat.
Conjugate
Unconjugated
Form
Liquid
Purification
Antigen affinity chromatography
Storage buffer
Dulbecco's PBS, pH 7.3, with 1mg/ml BSA, 50% glycerol
Contains
0.05% sodium azide
Storage Conditions
-20°C
Tested Applications
Dilution *
Flow Cytometry (Flow)
3-5 µg/million cells
Immunocytochemistry (ICC)
1 µg/ml
Immunofluorescence (IF)
1 µg/ml
Western Blot (WB)
Assay Dependent
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Eukaryotic initiation factor 4E binding protein 1 (4E-BP1), also known as PHAS, is a ~20 kDa member of a family of eIF4E-binding proteins whose binding affinity to eIF4E is regulated by its phosphorylation. It inhibits cap-dependent translation by binding to eIF4E on the same site that overlaps the binding site for eIF4G, preventing its binding to the latter and eventually leading to an increase in mRNA translation. The phosphorylation of 4E-BP1 is critical in determining cell fate by controlling translation initiation and apoptotic potency. 4E-BP1 is hyperphosphorylated in response to several external stimuli including hormones, growth factors, mitogens, cytokines and G-protein–coupled receptors and in response to stress conditions including nutrient deprivation. The phosphorylation of these sites is believed to occur in an orderly fashion where phosphorylation of threonine 37 and 46 by FRAP/mTOR is a priming step for subsequent phosphorylation of 4E-BP1 at the carboxy-terminal sites. Under normoxic conditions, increased VEGF expression, resulting from inhibition of 4E-BP1, contributes to efficient angiogenesis and metastatic brain growth through activated integrin alphav beta3.
原厂资料:
注意事项:
For Research Use Only. Not for use in diagnostic procedures.